These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23746164)

  • 1. Tubulin inhibitors: a patent survey.
    Nepali K; Ojha R; Sharma S; Bedi PM; Dhar KL
    Recent Pat Anticancer Drug Discov; 2014 May; 9(2):176-220. PubMed ID: 23746164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
    Li L; Jiang S; Li X; Liu Y; Su J; Chen J
    Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulins - the target for anticancer therapy.
    Vindya NG; Sharma N; Yadav M; Ethiraj KR
    Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of tubulin inhibitors that interact with the colchicine binding site.
    Lu Y; Chen J; Xiao M; Li W; Miller DD
    Pharm Res; 2012 Nov; 29(11):2943-71. PubMed ID: 22814904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
    Shi Q; Chen K; Morris-Natschke SL; Lee KH
    Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
    Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
    J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL
    Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting microtubules for cancer chemotherapy.
    Zhou J; Giannakakou P
    Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Wu X; Wang Q; Li W
    Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrostatic contributions to colchicine binding within tubulin isotypes.
    Huzil JT; Barakat K; Tuszynski JA
    Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
    Sharma S; Gupta MK; Saxena AK; Bedi PM
    Anticancer Agents Med Chem; 2017; 17(2):230-240. PubMed ID: 27141882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.